Cwm LLC Sells 7,070 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

CWM LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 37.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,725 shares of the medical research company's stock after selling 7,070 shares during the quarter. CWM LLC's holdings in Thermo Fisher Scientific were worth $5,834,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. One Charles Private Wealth Services LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock valued at $260,000 after buying an additional 20 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Holderness Investments Co. lifted its stake in shares of Thermo Fisher Scientific by 1.7% during the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock valued at $664,000 after buying an additional 21 shares in the last quarter. Port Capital LLC raised its stake in Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after purchasing an additional 22 shares in the last quarter. Finally, Clark Capital Management Group Inc. raised its holdings in Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after buying an additional 23 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on TMO shares. UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $500.00 to $460.00 in a report on Tuesday, July 8th. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $573.00 to $553.00 and set an "outperform" rating for the company in a research report on Friday. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $599.30.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 1.6%

Shares of NYSE:TMO traded down $6.77 during midday trading on Friday, reaching $418.21. The company had a trading volume of 366,090 shares, compared to its average volume of 2,011,709. The business's 50 day moving average price is $410.13 and its 200 day moving average price is $473.73. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a market cap of $157.87 billion, a PE ratio of 24.54, a P/E/G ratio of 2.21 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the business posted $5.11 earnings per share. The firm's quarterly revenue was up .2% compared to the same quarter last year. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.